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Endosomal sorting complexes required for transport
(ESCRT) recognize ubiquitinated cargo and catalyze
diverse budding processes including multivesicular
body biogenesis, enveloped virus egress, and cyto-
kinesis. We present the crystal structure of an
N-terminal fragment of the deubiquitinating enzyme
AMSH (AMSHDC) in complex with the C-terminal
region of ESCRT-III CHMP3 (CHMP3DN). AMSHDC
folds into an elongated 90 A˚ long helical assembly
that includes an unusual MIT domain. CHMP3DN is
unstructured in solution and helical in complex with
AMSHDC, revealing a novel MIT domain interacting
motif (MIM) that does not overlap with the CHMP1-
AMSH binding site. ITC and SPR measurements
demonstrate an unusual high-affinity MIM-MIT inter-
action. Structural analysis suggests a regulatory role
for the N-terminal helical segment of AMSHDC and
its destabilization leads to a loss of function during
HIV-1 budding. Our results indicate a tight coupling
of ESCRT-III CHMP3 and AMSH functions and pro-
vide insight into the regulation of ESCRT-III.
INTRODUCTION
Internalization of plasma membrane receptors by endocytosis is
regulated by ubiquitination and leads to receptor sorting into in-
tralumenal vesicles at the endosome giving rise to multivesicular
bodies (Babst, 2005; Saksena et al., 2007; van der Goot and
Gruenberg, 2006). The sorting process is catalyzed by ESCRTs
(endosomal sorting complexes required for transport) and their
associated molecules (Hurley, 2008; Peel et al., 2011; Saksena
et al., 2007). Part of the samemachinery is recruited by some en-
veloped viruses to facilitate budding (Bieniasz, 2009; Hartlieb
and Weissenhorn, 2006; Morita and Sundquist, 2004; Usami
et al., 2009) and during cytokinesis of eukaryotes (Carlton and
Martin-Serrano, 2007; Carlton and Martin-Serrano, 2009; Morita
et al., 2007) and Crenarchaea (Ghazi-Tabatabai et al., 2009; Lin-
da˚s et al., 2008).Structure 19, 1149–The ESCRT pathway is linked to the activity of deubiquitinating
enzymes (deubiquitinase, DUB, or ubiquin hydrolase or deubi-
quitylating enzyme) in order to maintain a constant pool of ubiq-
uitin (Komander et al., 2009). DUB Doa4 has an essential recy-
cling role in the yeast MVB pathway (Amerik et al., 2000) and
controls the function of ESCRTs (Nikko and Andre´, 2007). The
mammalian MVB pathway employs several DUBs including
AMSH (associated molecule with the Src homology 3 domain
of STAM, also known as STAMBP) (McCullough et al., 2004),
AMSH-LP (AMSH-like protein) (Sato et al., 2008), and UBPY
(Ub-specific protease Y) (Alwan and van Leeuwen, 2007). Both
AMSH and UBPY are recruited early in the pathway via interac-
tion with the ESCRT-0 subunit STAM (McCullough et al., 2006;
Mizuno et al., 2006; Row et al., 2006) and their localization to
early endosomes is supported by interaction with the clathrin
heavy chain (Nakamura et al., 2006).
Deubiquitination by AMSH is thought to precede cargo incor-
poration into MVB vesicles and lysosomal degradation (Alwan
et al., 2003; Dupre´ and Haguenauer-Tsapis, 2001). Depletion
of AMSH was reported to increase degradation of epidermal
growth factor receptor (EGFR) (McCullough et al., 2004). In
contrast a dominant-negative form of CHMP3 prevents AMSH
localization to the endosome, which, in turn, inhibits EGFR
degradation (Ma et al., 2007). Other studies implicate UBPY in
the control of EGFR ubiquitination (Alwan and van Leeuwen,
2007; Mizuno et al., 2005; Row et al., 2006). Besides EGFR,
AMSH is involved in downregulation of the calcium-sensing
receptor (Reyes-Ibarra et al., 2007), G protein-coupled receptors
(Hislop et al., 2009), the protease-activated receptor 2 (Hasdemir
et al., 2009), and the CXCR4 chemokine receptor (Sierra et al.,
2010). The latter study suggests that AMSH not only regulates
cargo ubiquitination but also ubiquitination of the endocytic ma-
chinery (Sierra et al., 2010). Furthermore, depletion of AMSH
leads to defects in cytokinesis (Mukai et al., 2008) and inactive
AMSH exerts a dominant-negative effect on retrovirus budding
(Agromayor and Martin-Serrano, 2006; Zamborlini et al., 2006).
The N terminus of AMSH is predicted to contain a MIT domain
(Tsang et al., 2006). This is followed by a central proline-rich
region providing the framework for STAM SH3 domain binding
(Tanaka et al., 1999), whichwas suggested to control the isopep-
tidase activity of the C-terminal JAMM domain, a metallo-
protease with specificity for K63-linked polyubiquitin chains
(McCullough et al., 2006; Sato et al., 2008). AMSH interacts1159, August 10, 2011 ª2011 Elsevier Ltd All rights reserved 1149
Table 1. Data Collection and Refinement Statistics
Native SeMet
Data collection
Space group P41 P41
Cell dimensions
a = b, c (A˚) 45.97, 206.91 45.92, 206.90
Peak
Wavelength (A˚) 0.9760 0.9795
Resolution (A˚) 44.861.75 (1.84–1.75) 69.84–2.90 (3.06–2.90)
Rmerge 0.08 (0.64) 0.14 (0.52)
I / sI 5.1 (1.2) 5.1 (1.4)
Completeness (%) 99.8 (100.0) 99.9 (100.0)
Redundancy 3.3 (3.3) 4.1 (4.2)
Refinement
Resolution (A˚) 1.75
No. reflections 141,404 (20,743)
Rwork / Rfree 0.19/0.23
No. atoms
Protein 2698
Water 386
B-factors
Protein 32.56
Water 45.55
Rmsd
Bond lengths (A˚) 0.02
Bond angles () 1.29
Values in parentheses are for highest resolution shell.
Structure
Crystal Structure of AMSH-CHMP3with ESCRT-III CHMP1 (Agromayor and Martin-Serrano, 2006;
Tsang et al., 2006), CHMP2A and CHMP3 (Agromayor and
Martin-Serrano, 2006; Kyuuma et al., 2007; Ma et al., 2007;
McCullough et al., 2006; Tsang et al., 2006; Zamborlini et al.,
2006) as well as Ist1 (Agromayor et al., 2009). ESCRT-III proteins
are autoinhibited in the cytosol (Bajorek et al., 2009; Lata et al.,
2008a; Zamborlini et al., 2006). Activation leads to membrane
interaction (Muziol et al., 2006; Shim et al., 2007) and polymeri-
zation in vitro (Bajorek et al., 2009; Ghazi-Tabatabai et al.,
2008; Lata et al., 2008b; Pires et al., 2009) and in vivo inducing
membrane deformation (Hanson et al., 2008). Current models
implicate ESCRT-I and II in vesicle formation (Wollert and Hurley,
2010), while the ordered assembly of ESCRT-III catalyzes mem-
brane fission (Fabrikant et al., 2009; Saksena et al., 2009; Teis
et al., 2008; Wollert et al., 2009). ESCRT-III proteins contain
MIT domain interactingmotifs (MIMs) within their C termini which
bind to MIT domains of VPS4 and spastin (Kieffer et al., 2008;
Obita et al., 2007; Stuchell-Brereton et al., 2007; Yang et al.,
2008).
In order to understand the structural basis of the AMSH-
CHMP3 interaction, we defined an N-terminal AMSH domain
(AMSHDC) by proteolysis that allowed the isolation of a soluble
complex with a C-terminal fragment of CHMP3. The crystal
structure of AMSHDC-CHMP3DN reveals an unconventional
MIT domain within AMSHDC. The CHMP3 C terminus adopts
a helical conformation upon binding and the molecular details
of the interaction provide a novel MIM sequence motif. Although
CHMP3 binds with high affinity to AMSH, ESCRT-III CHMP1A
and B show only micromolar interactions. Mutagenesis studies
suggest further that AMSHemploys a different molecular surface
for CHMP1 interaction. Structural analyses indicate that the
N-terminal helix preceding the MIT domain is mobile consistent
with data demonstrating that this regionmight control the activity
of AMSH during HIV-1 budding. Although the CHMP3-AMSH
interaction site overlaps with the VPS4 binding site the high KD
renders it unlikely to be displaced by VPS4.
RESULTS
Determination of a Minimal AMSH-CHMP3 Complex
Trypsin proteolysis of the AMSH(1-206)-CHMP3 complex
described previously (Lata et al., 2008a) was used to identify
AMSH residues 1 to 146 (AMSHDC) as a stable core fragment.
N-terminally His-tagged AMSHDC showed limited solubility on
its own but produced a monodisperse complex in association
with a C-terminal fragment of CHMP3 containing residues 183
to 222 (CHMP3DN). The AMSHDC-CHMP3DN complex was
purified by size exclusion chromatography and complex forma-
tion was confirmed by detection of the CHMP3DN peptide in the
elution peak by mass spectrometry.
In order to compare the affinity of AMSH to CHMP3DN with
previous measurements employing full-length CHMP3 (Lata
et al., 2008a), MBP-AMSH(1-206) was used for ITC analysis
with CHMP3DN, which produced an equilibrium dissociation
constant (KD) of 63 ± nM (enthalpy DH = 15.1 ± 0.09 kcal/mol)
(see Figures S1A and S1B available online). MBP-AMSH(1-146)
was constructed to determine whether a shorter form of AMSH
influences binding to CHMP3DN. SPR measurements with His-
MBP-CHMP3DN coupled to the chip and MBP-AMSHDC as1150 Structure 19, 1149–1159, August 10, 2011 ª2011 Elsevier Ltd Aanalyte revealed a KD of 113 nM based on the association
constant (ka) of 6.79 10
3 M-1 s-1 and the dissociation constant
(kd) of 7.64 10
4 s-1 confirming the high-affinity interaction
observed with the longer AMSH(1-206) construct (Figure S1C).Structure of the AMSHDC-CHMP3DN Complex
The structure of AMSHDC in complex with CHMP3DN was
determined from a selenomethionine-containing crystal using
the single wavelength anomalous dispersionmethod and diffrac-
tion data to 1.75 A˚ (Table 1). This resulted in a readily interpret-
able electron density map (Figure 1A) revealing two complexes
in the asymmetric crystal unit. AMSHDC folds into a 90 A˚ long
elongated helical assembly (Figure 1B). The N-terminal a-helical
segment 1 folds back onto a helices 2 and 5 which are followed
by an extended conformation. Helices 2, 3, and 4-5 form a three
helical bundle structure reminiscent of a MIT domain although
a break in helix 4 at Ile 98 disrupts the helical continuity of the
third helix. The latter extends far beyond the core of the MIT
domain and spans a distance of 90 A˚ (Figure 1B). However,
the conserved features of a MIT domain are evident from super-
positioning of the Ca atoms with the structure of the VPS4 MIT
domain revealing a rmsd of 2.6 A˚ (Figure 1C).
CHMP3DN residues 200–222 adopt a helical conformation in
the complex burying the solvent-accessible surface of 1659 A˚2
on AMSHDC and CHMPDN, while CHMP3DN is unstructured
in solution (Figure S2A). It is likely more structured in full-lengthll rights reserved
Figure 1. Crystal Structure of AMSH in Complex with CHMP3
(A) Stereo image of the experimental electron density map obtained after SAD
phasing.
(B) Ribbon representation of AMSHDC (blue) in complex with CHMP3DN
residues 200–222 (yellow).
(C) Overlay of the Ca atoms of AMSHDC (blue) with the VPS4 MIT domain
(PDB 2JQ9) (green ribbon).
Figure 2. The CHMP3N-AMSHDC Interaction Is Dominated by Polar
Contacts
(A) Closeup of the CHMP3-AMSH interactions. Hydrogen bonds and salt
bridges along the CHMP3 helical segment mediate high-affinity interaction.
(B) Sequence alignment of the C-terminal regions of CHMP3, CHMP1A,
CHMP1B, and CHMP2A. CHMP3 residues contacting AMSH are indicated by
red asterisks (polar contact), blue asterisks (main chain polar contacts), and
black asterisks (hydrophobic contacts).
(C) Pull-down of CHMP3 by wild-type and mutant His-AMSHDC confirms the
essential role of polar interactions. The left panel of the SDS-PAGE shows the
input proteins and the right panel the pull-down of CHMP3 by wild-type and
mutant His-AMSHDC, as indicated. The K88A mutant reveals a strongly
reduced interaction with CHMP3 and the E104 and K107A mutants show
a complete loss of interaction in this assay.
Structure
Crystal Structure of AMSH-CHMP3CHMP3, since the overall helical content is slightly higher for full-
length CHMP3 (60% a-helical corresponding to 133 residues)
compared with CHMP3(9-183) (68% a-helical corresponding
to 119 residues) (Figure S2B), although both proteins reveal
similar melting temperatures of 60C indicating that the C
terminus does not contribute substantially to the stability of
CHMP3 in the autoinhibited form (Figure S2C). CHMP3DN inter-
acts with the MIT domain of AMSH diagonal along a groove
made up by helices 3 and 4/5. The orientation of interaction is
parallel with respect to the positions of bothC termini (Figure 1B).
CHMP3DN residues 184–199 do not contribute to the interaction
and are disordered in the structure. The complex is stabilized by
a hydrogen bond between Glu207 and Tyr80 and salt bridges
between Glu203-Lys88, Arg216-Glu104, and Arg221-Glu72.
The last C-terminal residue, Ser222, of CHMP3 is capped by
AMSHDC Lys107, which forms a salt bridge with the carboxyl
group of Ser222 and hydrogen bonds with the carbonyls of
Thr219 and Leu220 (Figure 2A). Hydrophobic contacts play
a minor role and include Leu210 interactions with Ile71 and
Tyr80 as well as Leu220 contacts with Asn64 and Lys107
(Figure 2B). Mutagenesis of AMSH interface residues Lys88,
Glu104, and Lys107 to Ala confirmed the importance of the
salt bridges and hydrogen bonds for interaction. While
AMSHDC-K88A recovered a faint amount of CHMP3 in a pull-
down, AMSHDC-E104A and AMSHDC-K107A failed to pull
down CHMP3 (Figure 2C). The effect of the mutations on binding
were confirmed by SPR. AMSHDC-K88A produced a KD of
1.2 mM (ka 2.8 ± 0.094 10
4 M-1 s-1 and kd of 3.1 ± 0.033
103 s-1) and AMSHDC-E104A a KD of 5.2 mM (ka 0.42 ± 0.016
104 M-1 s-1 and kd of 2.2 ± 0.029 10
3 s-1). Thus, both mutations
reduced binding by a factor 30 and 130, respectively, comparedStructure 19, 1149–with the 40 nM KD of wild-type AMSHDC employing the same
SPR setup. Notably, the mutations did not change the cellular
localization when introduced into GFP-AMSH(D348A) (Fig-
ure S3), indicating that they did not alter the overall structure.
Previous crystal structures of MIT-CHMP interactions reveal
an important role for hydrophobic ESCRT-III MIM residues
(Kieffer et al., 2008; Obita et al., 2007; Stuchell-Brereton et al.,
2007; Yang et al., 2008), while the AMSHDC-CHMP3DN struc-
ture highlights the importance of polar interactions leading to
a novel MIM sequence motif (Table 2). Because CHMP1A,
CHMP1B, and CHMP2A were reported to interact with AMSH
(Agromayor and Martin-Serrano, 2006; Tsang et al., 2006), the
limited sequence conservation with CHMP3 (Figure 2B) pre-
dicts that either they bind AMSH similarly, but with lower affinity,
or they use a different strategy for interaction. Accordingly SPR
measurements showed a much lower affinity for CHMP1A and
CHMP1B interaction with AMSH (Figure S1D). Both GST-
CHMP1ADN and GST-CHMP1BDN bound to the analyte1159, August 10, 2011 ª2011 Elsevier Ltd All rights reserved 1151
Table 2. ESCRT-III MIT Domain Interacting Motifs
MIM1 Lx2RLxxLR a 2, 3 CHMP1B, 2B VPS4 (Stuchell-Brereton et al., 2007)
MIM4 Ex3Ex2Vx2Vx2RLxTLRx a 3, 4/5 CHMP3 AMSH
MIM1 E/Dx2Lx2RLxxLK/R a 2, 3 Vps2, Did2 VPS4 (Obita et al., 2007)
MIM2 VxLPxVPSx2LP a 1, 3 CHMP4, 6 VPS4 (Kieffer et al., 2008)
MIM2 RxxLxPxLPxPP a 1, 3 Saci1337 Saci1372 (Samson et al., 2008)
MIM3 Sx2TSxAx2EQDx2SxRV a 1, 3 CHMP1B spastin (Yang et al., 2008)
The motifs have been either reported in the cited literature or deduced from the structures reporting the corresponding contact residues.
Structure
Crystal Structure of AMSH-CHMP3MBP-AMSH(1-206) with KDs of 1.49 and 1.16 mM, respectively,
based on the association constants (ka) of 3.89 ± 0.06 3
103 M-1 s-1 (CHMP1A) and 2.52 ± 0.03 3 103 M-1 s-1 (CHMP1B)
and the dissociation constants (kd) of 5.81 ± 0.09 3 10
3 s-1
(CHMP1A) and 2.92 ± 0.08 3 103 s-1 (CHMP1B). Probing
AMSH mutants AMSHDC-K88A and AMSHDC-E104A for
CHMP1B interaction demonstrates that both mutants are still
capable to pull down GST-CHMP1BDN (Figure S1E); this might
indicate that AMSH employs different interaction surfaces for
CHMP1B andCHMP3. Furthermore the AMSH binding site over-
laps with the VPS4 site on CHMP3 (Table 2) (Obita et al., 2007;
Stuchell-Brereton et al., 2007), consistent with the finding that
AMSHCHMP3 and VPS4 binding are exclusive (data not shown).Structural Homology of the N-Terminal Domains
of AMSH and USP8
A search for homologous structures (Dietmann et al., 2002) re-
vealed high similarity to the N-terminal domain of the ubiquitin-
specific protease 8 (USP8, also known as UBPY, Ubiquitin-
specific protease Y) (Avvakumov et al., 2006) as evidenced by
the rmsd of 2.9 A˚ upon overlay of the Ca backbone (Figure 3A).
The main difference between both structures is the detachment
of the N-terminal segment including a helix 1 from the core,
which mediates dimerization in case of USP8 (Avvakumov
et al., 2006). The N-terminal region (residues 1–27) of AMSH is
only stabilized by a hydrogen bond between His4 and Glu57
and a salt bridge between Arg14 and Glu117 (Figure 3B).
Although the N-terminal sequence of AMSH and UBPY diverge
substantially (Figure 4), it is possible that the N terminus ofFigure 3. Superpositioning of the Ca Atoms of AMSH and UBPY
Reveal a Regulatory Role of the N-Terminal Regions of AMSH and
UBPY
(A) Ribbon representation of the Ca overlay of AMSHDC (blue) and UBPY
(green) (PDB code 2A9U).
(B) Close up of the twomain contacts between AMSH helix 1 and helices 3 and
5 of the core.
1152 Structure 19, 1149–1159, August 10, 2011 ª2011 Elsevier Ltd AAMSHmight be able to detach and adopt a similar conformation
as in case of UBPY and vice versa the N terminus of UBPYmight
attach to the core as observed for AMSHDC. Thus the two
conformations observed in both structures might be part of
a common conformational control mechanism of AMSH and
USP8/UBPY.The N-Terminal Helix 1 of AMSH Is Required
for HIV-1 Budding
It has been previously shown that expression of catalytically
inactive AMSH fused to GFP or YFP alone or in coexpression
with full-length CHMP3 induces a dominant-negative effect on
HIV-1 and MLV budding (Agromayor and Martin-Serrano,
2006; Zamborlini et al., 2006). Expression of catalytic inactive
GFP-AMSH(D348A) had a mild effect on the kinetic of HIV-1
release as indicated by the accumulation of the Gag cleavage
intermediates CAp2 and p41 (Figure 5A, right panel, lane 3)
that define late assembly defects (Garrus et al., 2001; Go¨ttlinger
et al., 1991). However, coexpression of GFP-AMSH(D348A) with
CHMP3-Flag almost completely blocked HIV-1 release as indi-
cated by the absence of CA in the supernatant (Figure 5A, left
panel, lane 4) and the enhanced defect in Gag processing (Fig-
ure 5A, right panel, lane 4). Notably the intracellular distribution
of GFP-AMSH(D348A) resembles that of wild-type AMSH-HA
when coexpressedwith CHMP3-Flag (Figures 6A and 6B). Muta-
tion of the N-terminal residues His4Ala and Arg14Ala that
stabilize the interaction with the core (Figure 3B) within GFP-
AMSH(D348A) leads to the loss of the dominant effect when ex-
pressed alone or in combination with CHMP3-Flag as indicated
by the wild-type-like release of CA into the supernatant and
normal intracellular Gag processing (Figure 5A, lanes 5 and 6).
GFP-AMSH(D348A-H4R14A) expression levels were slightly
reduced in comparison to GFP-AMSH(D348A) (Figure 5A, lower
panel). GFP-AMSH(D348A-H4R14A) expression was also
altered from mostly cytoplasmic staining to accumulation at
a perinuclear region without notable concentration of CHMP3-
Flag (Figure 6C). Because the previous experiment showed
that a strong dominant-negative effect of GFP-AMSH(D348A)
depends on CHMP3 expression, we tested whether GST-
CHMP3(151-222) can pull down the N-terminal mutant (GFP-
AMSH[D348A-H4R14A]), which is no longer the case. Only a faint
band could be detected for the N-terminal mutant in comparison
to GFP-AMSH(D348A). Notably GFP-AMSH(D348A-H4R14A)
showed a lower expression level than GFP-AMSH(D348A)
(Figure 5B).
Expression of N-terminally MBP-tagged full-length AMSH in
Escherichia coli produced polydisperse AMSH, while recom-
binant AMSH expressed without tag was monodisperse,ll rights reserved
Figure 4. Sequence and Secondary Structure Alignment of AMSH, AMSH-LP, and UBPY
Human AMSH (accession code AAD05037) residues 1–146 were aligned to the corresponding fragments of AMSH-LP (accession code BAC77766) and UBPY
(accession code AAI10591). Residues contacting CHMP3 are indicated with blue triangles. Note that the CHMP3 contact residues are conserved between AMSH
and AMSH-LP but not UBPY. Secondary structures are shown for AMSH and UBPY (PDB code 2A9U).
Structure
Crystal Structure of AMSH-CHMP3indicating that N-terminal fusions of AMSH induce the formation
of polydisperse AMSH in vitro (Figure S4). This led us to perform
the HIV-1 budding assaywith catalytic inactive AMSH containing
a C-terminal HA-tag instead of a N-terminal GFP-tag in the pres-
ence and absence of CHMP3 expression. The results indicate
that expression of the catalytic inactive AMSH(HH335,337QQ)-
HA or CHMP3 alone has no effect on virus particle production
as measured by the detection of CA in the supernatant (Fig-
ure 5C, left panel, lanes 13). Only coexpression of both proteins
leads to a slight reduction in virion release and defects in intracel-
lular Gag processing (Figure 5C, lanes 3 and 4). This minor
assembly defect is lost, when AMSH(HH335,337QQ)-HA contain-
ing the N-terminal double mutant (His4Ala, Arg14Ala) is co-
expressed with CHMP3 since no reduction in particle production
is observed, consistent with the lack of intracellular Gag pro-
cessing defects (Figure 5C, lanes 5 and 6). The expression levels
of AMSH constructs were comparable (Figure 5C, lower panel)
and AMSH(HH335,337QQ)-HA shows cytoplasmic staining when
coexpressed with CHMP3, similar to wild-type AMSH-HA (Fig-
ures 6D and 6E). This indicates that the N-terminal fusion of
GFP is responsible for the dominant-negative effect of catalytic
inactive AMSHwhen coexpressedwith CHMP3 and this function
is lost upon destabilization of the N-terminal region, indicating
that the His4Ala and Arg14Ala positions are important for sup-
porting the dominant-negative effect.
DISCUSSION
Deubiquitinating enzymes (DUBs) AMSH and UBPY targeting
ESCRT-III play an important role in ESCRT-regulated processesStructure 19, 1149–(Komander et al., 2009; McDonald and Martin-Serrano, 2009;
Raiborg and Stenmark, 2009) and many ESCRT-III interaction
partners recognize sequence motifs located within the C ter-
minus of ESCRT-III family members (Agromayor and Martin-
Serrano, 2006; Obita et al., 2007; Scott et al., 2005; Stuchell-
Brereton et al., 2007; Yang et al., 2008; Zamborlini et al.,
2006). The crystal structure of AMSH in complex with CHMP3
demonstrates that the C-terminal CHMP3 MIM adopts a helical
conformation, which is induced by complex formation, since
the same peptide is unstructured in solution. However our CD
analysis also suggest that part of it might be structured within
full-length CHMP3 and thus contribute to the autoinhibited
conformation of CHMP3 (Bajorek et al., 2009; Lata et al.,
2008a; Zamborlini et al., 2006). The structure of AMSH contains
a region that resembles a MIT domain as predicted (Tsang et al.,
2006), which interacts with the CHMP3 MIM. However, we
propose that the structure does not qualify as a classical MIT
domain (Scott et al., 2005), due to the presence of an N-terminal
region including helix 1 and because of the 90 A˚-long extension
of helix 5 (corresponding to helix 3 of a MIT domain). This is
further supported by the poor solubility of the MIT-like domain
of AMSH on its own and by AMSHDC lacking helix 1 in vitro
(J.S. and W.W., unpublished data). However, the general mode
of target recognition is similar to that of MIT domains. CHMP3
binds in a helical conformation diagonal along a groove made
up by helices 3 (VPS4 MIT helix 2) and 4/5 (VPS4 MIT helix 3).
The AMSH-CHMP3 interaction site resembles VPS4 interactions
with CHMP1A or yeast Vps2p, which employ helices 2 and 3 for
the recognition of a shorter helical motif (MIM 1) (Stuchell-Brere-
ton et al., 2007) (Obita et al., 2007). In contrast the spastin MIT1159, August 10, 2011 ª2011 Elsevier Ltd All rights reserved 1153
Figure 5. Catalytic Inactive AMSH and CHMP3 Expression Inhibit
HIV-1 Budding
(A) (Left panel) Expression of catalytically inactive GFP-AMSH(D348A) exerts
a strong effect on HIV-1 budding when coexpressed with CHMP3 (lanes 3
and 4). In contrast expression of GFP-AMSH(D348A-H4A-R14A) alone or in
combination with CHMP3 has no effect on budding (lanes 5 and 6) comparable
to vector expression (lane 1) or CHMP3 expression alone (lane 2). (Right panel)
Western blot revealing the intracellular Gag processing. Only expression of
GFP-AMSH(D348A) alone and together with CHMP3 show a defect in intra-
cellular Gag processing (lanes 3 and 4), while the N-terminal mutant GFP-
AMSH(D348A-H4A-R14A) resembles the negative control (lane 1) and CHMP3
expression (lane 2). (Lower panel) western blot showing the expression levels
of the AMSH constructs.
Structure
Crystal Structure of AMSH-CHMP3
1154 Structure 19, 1149–1159, August 10, 2011 ª2011 Elsevier Ltd Adomain interacts with a helical segment of CHMP1B via its
helices 1 and 3 (Yang et al., 2008). The same groove between
helices 1 and 3 is employed by VPS4 to bind the CHMP6
MIM2 motif (Kieffer et al., 2008) and by Vps4 (Saci1372) from
Crenarchaea to interact with the MIM2-like motif present in
the ESCRT-III-like protein Saci1373 (Samson et al., 2008). The
general MIT-MIM contacts range from mostly hydrophobic
interactions observed in the VPS4-CHMP1A, Vps4p-Vps2p,
VPS4B-CHMP6 and Saci1372 (Vps4-like)-Saci1373 (ESCRT-II-
like) complexes (Kieffer et al., 2008; Obita et al., 2007; Samson
et al., 2008; Stuchell-Brereton et al., 2007) to a mixture of polar
and hydrophobic interactions in case of spastin MIT and
CHMP1B (Yang et al., 2008) to mostly polar contacts dominating
the AMSH-CHMP3 complex. Thus, the structure of the AMSH-
CHMP3 complex extends the diversity of MIT domain interaction
surfaces for peptide ligands.
AMSH was reported to interact not only with CHMP3 but also
with CHMP1A/B and CHMP2A (Agromayor and Martin-Serrano,
2006). SPR measurements show that both CHMP1A and B
interact with low micromolar affinities with AMSH. The low
sequence conservation between CHMP3 and CHMP1A/B and
the fact that two AMSH mutants that show up to a 130 times
lower CHMP3 binding activity still interact with CHMP1B, indi-
cate that CHMP1 and CHMP3 binding sites do not overlap.
This is further indirectly supported by the low sequence similarity
between AMSH and UBPY, although both bind CHMP1A/B
(Agromayor and Martin-Serrano, 2006; Row et al., 2006).
The60 nMKd for the CHMP3-AMSH interaction is to date the
highest Kd reported for an ESCRT-III MIM-MIT interaction. In
contrast spastin-MIT binds to CHMP1A with a Kd of 12 mM Kd
(Yang et al., 2008) approximately three times higher than the
30 mM determined for the VPS4-MIT-MIM1 and MIM2 interac-
tions (Kieffer et al., 2008; Obita et al., 2007; Samson et al., 2008;
Stuchell-Brereton et al., 2007). The high-affinity interaction
between CHMP3 and AMSH is mainly mediated by six salt
bridges along the CHMP3 helix compared with two salt bridges
in case of the spastin-MIT-CHMP1B interaction. Furthermore the
total solvent-accessible surface area buried upon complex
formation is 1650 A˚2 (20 residues) compared with 1946 A˚2 (24
residues) of the spastin-CHMP1B complex (Yang et al., 2008)
and 1238 A˚2 (15 residues) for the Vps4 MIT-Vps2 complex (Obita
et al., 2007). The importance of CHMP3 Arg216, which makes
a double-dent salt bridge with AMSH Glu104 and of an intact
CHMP3 C terminus, has been documented by mutagenesis(B) Pull-down of GFP-AMSH(D348A) (lanes 1 and 3) and GFP-AMSH(D348A-
H4R14A)-HA (lanes 2 and 4) with GST (lanes 1 and 2) and with GST-
CHMP3(151-222) (lanes 3 and 4). The western blot below shows the expres-
sion pattern of both GFP-AMSH constructs, and the panel on the side shows
the protein input used for the pull-down.
(C) (Left panel) Expression of catalytically inactive AMSH(HH335,337QQ)-HA
exerts a mild effect on HIV-1 budding when coexpressed with CHMP3 (lanes 3
and 4). In contrast expression of AMSH(HH335,337QQ-H4R14A)-HA alone or in
combination with CHMP3 has no effect on budding (lanes 5 and 6). (Right
panel) Western blot revealing the intracellular Gag processing. Only expres-
sion of AMSH(HH335,337QQ)-HA and CHMP3 show a defect in intracellular Gag
processing (lane 4), while the N-terminal mutant resembles that of
AMSH(HH335,337QQ)-HA expression (lane 3) or the vector control (lane 1).
(Lower panel) Western blot revealing similar expression levels for the different
AMSH constructs.
ll rights reserved
Figure 7. Molecular Model of AMSH in Complex with Membrane-
Associated CHMP3
AMSHcanbe recruited tomembranesearly in theESCRTpathwayviaESCRT-0
Stam. This might be independent of ESCRT-III CHMP3 interaction or both
processes could be linked. If AMSH interacts with activated CHMP3 present in
ESCRT-III polymers on membranes, the DUB activity could have an action
radius of >20 nm due to the long helical arm of AMSH and the flexible linkage of
the CHMP3 MIM to the core of CHMP3-mediating ESCRT-III polymerization.
Figure 6. The H4, R14 Mutations in Combination with GFP Alter the
Cellular Localization of AMSH when Coexpressed with CHMP3
(A) CHMP3-Flag and AMSH-HA.
(B) CHMP3-Flag and catalytic inactive GFP-AMSH(D348A).
(C) CHMP3-Flag and catalytic inactive GFP-AMSH(D348A-H4A-R14A).
(D) CHMP3-Flag and inactive AMSH-HA carrying the mutations H335Q and
H337Q, which render it catalytic inactive as well as the N-terminal mutations
H4A and R14A. The scale bar is 10 mM.
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Crystal Structure of AMSH-CHMP3analysis. Notably, deletion of residues 221 and 222 lead to a loss
of interaction (Zamborlini et al., 2006) consistent with the struc-
tural details revealing that CHMP3 Arg221 forms a salt bridge
with AMSH Glu72 and the carboxyl group of the C-terminal
CHMP3 Ser222 contacts AMSH Lys107 via a salt bridge. Vice
versa we show here that mutagenesis of AMSH residues
Lys88, Glu104, and Lys107 abrogates CHMP3 binding in vitro.
In yeast, Doa4 DUB activity has been genetically linked to Snf7
(CHMP4) and Bro1, which leads to endosomal recruitment after
ESCRT-III assembly (Luhtala and Odorizzi, 2004) (Amerik et al.,
2006). It is thus conceivable that AMSH is also recruited to
ESCRT-III polymers assembled on cellular membranes (Saksena
et al., 2009; Teis et al., 2008). The helical extension of the MIT
domain could then serve as a long arm to position the DUB
activity (Sato et al., 2008) >20 nm away from the ESCRT-III poly-
mer (Figure 7), thus reaching into the vesicle formed by ESCRT-I
and II (Wollert and Hurley, 2010) for deubiquitination of cargo.
The MIM 1 sequence motif responsible for VPS4 interaction
(Stuchell-Brereton et al., 2007) overlaps with the CHMP3-
AMSH binding site and superpositioning of the VPS4A-CHMP1B
and VPS4B-CHMP2A structures with AMSH-CHMP3 demon-
strates the overlap of the bindingmotifs, which prohibits simulta-Structure 19, 1149–neous binding of AMSH and VPS4 to CHMP3. Although we do
not know the sequence of recruitment, it is most likely that
AMSH has to be released from CHMP3 before interacting with
VPS4. Since the AMSH interaction is 300-fold tighter than
VPS4 binding, a specificmechanismmust exist such as potential
conformational changes that release AMSH from CHMP3 before
it becomes a target for VPS4-driven ESCRT-III disassembly
(Babst et al., 1998).
The structure of AMSHDC resembles the structure of the
N-terminal domain of USP8/UBPY, a DUB acting in the ESCRT
pathway (Avvakumov et al., 2006). This structural similarity is
not evident from the low sequence similarity of AMSH and
UBPY. One notable structural difference is however the different
conformation of a short N-terminal segment that is attached to
the core of the monomer in case of AMSHDC and is detached
in UBPY-mediating dimerization in the crystal (Avvakumov
et al., 2006). N-terminal fusions of catalytic inactive AMSH
have been shown previously to exert a dominant-negative effect
on HIV-1 and MLV budding (Agromayor and Martin-Serrano,
2006; Zamborlini et al., 2006), which was confirmed by our
assay. However, destabilization of the N terminus by structure
based mutagenesis led to the loss of the dominant-negative
effect indicating that an intact N terminus is important for
budding inhibition, which correlated with the ability to interact
with CHMP3. Since we observed the dramatic effect of the
N-terminal MBP fusion on the oligomerization states of AMSH
in vitro we reexamined the role of AMSH in HIV-1 budding by
using C-terminal-tagged versions of AMSH. This showed indeed
that catalytic inactive AMSH-HA has no effect on HIV-1 budding
and only a mild effect upon coexpression with CHMP3, which
was abrogated by the AMSH mutations that destabilize helix 1
interaction with the core. We conclude from these results that
(1) N-terminal fusions of AMSH change the function of AMSH,
which renders it dominant negative in combination with its
ESCRT-III binding partner CHMP3. This function requires an1159, August 10, 2011 ª2011 Elsevier Ltd All rights reserved 1155
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Crystal Structure of AMSH-CHMP3intact N terminus and is disturbed by His4 and Arg14 muta-
tions. (2) Destabilization of the N terminus is not sufficient to
induce a strong dominant-negative effect of AMSH-HA, indi-
cating that mutations of His4 and Arg14 interfere with the
structural changes required to become dominant negative. In
summary we have provided structural principles of a novel
MIT-like MIM interaction. The structural and functional analyses
demonstrate that conformational plasticity of the N terminus
might play an important role in the regulation of AMSH activity.
This might entail activation of the catalytic activity by either
STAM binding (McCullough et al., 2006) or other regulatory
factors.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of AMSH and CHMP3
AMSH containing residues 1–206 (AMSH(1-206)) was expressed and purified
as described (Lata et al., 2008a). AMSH(1-206) in complex with full-length
CHMP3 (Lata et al., 2008a) was subjected to limited proteolysis with trypsin
at a 1:500 (w/w) ratio and bands were separated on a 12% SDS-PAGE. A
prominent smaller fragment of AMSH was analyzed by mass fingerprinting
and mapped to residues 1–146 (AMSHDC). AMSHDC was cloned into the
vector pPROEX HTa (Invitrogen) and into a modified version of the
pMalC2G-TEV vector (Bracher andWeissenhorn, 2002) to produceHis-tagged
AMSHDC and MBP-AMSHDC. CHMP3(183-222) was cloned into the vector
pBADM-41 (His-MBP fusion protein with TEV protease cleavage site) to
produce His-MBP-CHMP3DN. Full-length AMSH was cloned into pMalC2G-
TEV (MBP-AMSH) and tag-less AMSH was cloned into vector pASK-IBA43-
plus. CHMP1A (residues 123–196) and CHMP1B (residues 126–199) were
cloned into vector pGEX-TEV. His-AMSHDC, MBP-AMSHDC, His-MBP-
CHMP3DN,MBP-AMSH, AMSH, GST-CHMP1A, and GST-CHMP1B were ex-
pressed in E. coli cells BL21 codon+ or E. coliRosetta. MBP-AMSH and AMSH
expression in E. coli was induced at 16C overnight. AMSH mutations K88A,
E104A and K107A were introduced into His-tagged AMSHDC and GFP-
AMSH(D348A) by using standard mutagenesis procedures.
His-AMSHDCwas solubilized in buffer A (20mMTris [pH 8.5], 100mMNaCl)
and purified on a Ni2+-Sepharose column. His-MBP-CHMP3DNwas purified in
buffer A on an amylase column, which produced mixtures of His-MBP-
CHMP3DN and truncated forms corresponding to free MBP. For ITC and CD
analyses, His-MBP-CHMP3DN was further purified by anion exchange chro-
matography followed gel filtration chromatography on a Superdex-75 (GE
Healthcare) column in buffer A. GST-CHMP1A and GST-CHMP1B were puri-
fied on a glutathione column in PBS buffer followed by gel filtration chromatog-
raphy in PBS buffer. His-MBP-CHMP3DN and His-AMSHDC were mixed in
a 2:1 molar ratio and the tags were cleaved by TEV protease cleavage at
4C. His tags and uncleaved proteins were removed by passing the complex
over a Ni2+-Sepharose column in buffer A. A final purification step included
a gel filtration on a Superdex-75 column in buffer B (10 mM HEPES [pH 8.0],
100 mM NaCl). The complex was concentrated to 3.3 mg/ml. Selenomethio-
nine substituted His-AMSHDC was produced as described (Doublie´, 1997)
and the complex with CHMP3DN was purified as described above for the
native complex and concentrated to 3.6 mg/ml. MBP-AMSHDC was purified
in buffer A on an amylose affinity column in buffer A coupled to a second puri-
fication step on a Superdex 75 gel filtration column in buffer A. MBP-AMSH
was purified on an amylose column in buffer C (20 mM Tris [pH 8.5], 100
NaCl) followed by gel filtration in buffer C. AMSH was purified on a Q Sephar-
ose column in buffer D (25 mM Tris [pH 8.5], 25 mM NaCl) by applying a NaCl
gradient in buffer D. Further purification included a gel filtration on a Superdex
200 column in buffer C. His-tagged AMSHDC mutants were purified as wild-
type AMSHDC in buffer A (20 mM Tris [pH 8.5], 100 mM NaCl) on a Ni2+-
Sepharose column followed by gel filtration on superdex-75 in buffer B. The
experimental conditions for the pull-downs are described in the Supplemental
Experimental Procedures.
Isothermal titration calorimetry and surface plasmon resonance experi-
ments were carried out as described in the Supplemental Experimental
Procedures.1156 Structure 19, 1149–1159, August 10, 2011 ª2011 Elsevier Ltd ACrystallization, Diffraction Data Collection, and Structure Solution
of AMSHDC in Complex with CHMP3DN
Initial crystallization conditions for the AMSHDC-CHMP3DN complex at
3.3 mg/ml were determined by using 200 nl sitting drops and 1.9 M sodium
malonate as reservoir solution. Crystals were improved by mixing the complex
at 7.2mg/ml with an equal volume of 2.2M sodiummalonate, which resulted in
microcrystals. Larger crystals were grown by streak seeding the microcrystals
into fresh drops mixed with 1.8 to 2.2 M sodium malonate. Crystals grown in
1.8M sodiummalonatewere flash-frozen in liquid nitrogen in the crystallization
buffer supplemented with 30% glycerol as cryoprotectant. A native data set
was collected at 1.75 A˚ resolution at the ESRF beam line (Grenoble) ID-14-4.
Selenomethione substituted AMSHDC in complex with CHMP3DN was crys-
tallized as described above for the native complex, except that several rounds
of seeding were required to obtain diffraction quality crystals. A single wave-
length anomalous dispersion (SAD) data set was collected at 100 K at beam
line ID14-4 (ESRF, Grenoble) at the peak wavelength of the selenium K edge
(wavelength 0.9795 A˚). The data were processed with MOSFLM (Leslie,
1992) and Scala (CCP4, 1994; Evans, 2006). The crystals belong to space
group P41 with unit cell dimensions of a, b = 45.97 A˚, c = 206.91 A˚ and two
complexes per asymmetric unit. Data were initially analyzed using the Auto-
Rickshaw platform at EMBL Hamburg (Panjikar et al., 2005). Selenium sites
were localized at a resolution of 2.8 A˚ with the program SHELXD (Schneider
and Sheldrick, 2002). The correct hand for the substructure was determined
using the programs ABS (Hao, 2004) and SHELXE (Sheldrick, 2002). Initial
phases were calculated after density modification using the program SHELXE
(Sheldrick, 2002) and model building was performed with the program ARP/
wARP (Perrakis et al., 1999). This initial model was used as a search model
for molecular replacement with MOLREP (CCP4, 1994) employing the native
data to 1.75 A˚ resolution. Automatic model building was completed with
ARP/wARP (Perrakis et al., 1999), manual model building using COOT (Emsley
and Cowtan, 2004) and refinement with the program Refmac (Murshudov
et al., 1997). The structure contains AMSH residues 2–142 and CHMP3 resi-
dues 200 to 222 and was refined to an R factor of 19% and an Rfree of
23.0%. 99.67% of the residues are within the most favored and allowed
regions of a Ramachandran plot (CCP4, 1994). All molecular graphics figures
were generated with PYMOL (W. Delano; http://www.pymol.org/).
Analysis of Virus Particle Production
293T cells (1.2 3 106) were seeded into T25 flasks and transfected 24 hr later
using a calcium phosphate precipitation technique. The cultures were trans-
fected with 1.5 mg HXBH10, which encodes WT HIV-1, together with GFP-
AMSH(D348A) (Zamborlini et al., 2006) or GFP-AMSH(D348A0H4R14A)
and/or pcDNA3.1 vectors expressing CHMP3, AMSH(HH335,337QQ)-HA or
AMSH(HH335,337QQ)-HA harboring the H4,R14A mutations or the appropriate
empty vector (0.5 mg each). The total amount of transfected DNA was brought
to 8 mg with carrier DNA (pTZ18U). Twenty-four hours after transfection, the
cells were lysed in RIPA buffer (140 mM NaCl, 8 mM Na2HPO4, 2 mM
NaH2PO4, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.05% SDS), and
the culture supernatants were clarified by low-speed centrifugation and
passaged through 0.45 mm filters. Virions released into the medium were pel-
leted through 20%sucrose cushions and analyzed by SDS-PAGE andwestern
blotting with anti-HIV CA antibody 183-H12-5C (Chesebro et al., 1992).
Proteins in the cell lysates were detected by western blotting with anti-HIV
CA antibody or rabbit anti-GFP serum (Molecular Probes). The pull-down of
GFP-AMSH(D348A) and GFP-AMSH(D348A0H4R14A) employing GST-
CHMP3(151-222) was performed as described (Zamborlini et al., 2006).
Immunofluorescence Analysis
PcDNA3.1 expression constructs of wild-type AMSH-HA, AMSH(HH335,337QQ)-
HA carrying the His4 and Arg14 to Ala mutations, CHMP3-Flag and
GFP-AMSH(D348A), GFP-AMSH(D348A-H4R14A), GFP-AMSH(D348A-K88A),
GFP-AMSH(D348A-E104A), and GFP-AMSH(D348A-K107A) were transfected
into 293T cells using standard methods. For indirect immunofluorescence
(IIF) 293T cellswere cultured on coverslips and fixedwith 4%paraformaldehyde
for 20 min at 4C. The GFP constructs were directly visualized and for the other
constructs coverslips were incubated with anti-HA-tag or anti-Flag-tag anti-
bodies in PBS for 1 hr, at room temperature. Slides were washed three times
with PBS, followed by the secondary antibody incubation at room temperaturell rights reserved
Structure
Crystal Structure of AMSH-CHMP3for 1 hr (Alexa488 or 594 coupled anti-mouse or anti-rabbit goat antibodies in
PBS).After threewasheswithPBS, slidesweremounted inMowiol andanalyzed
by confocal microscopy.
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